Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Multivariate analyses showed that comparisons of drug survival did not reach statistical significance for infliximab, adalimumab or etanercept for first‐line therapy; however, the comparison between ustekinumab and all three biologics for second‐line therapy and between ustekinumab and etanercept for third‐line therapy showed significantly better survival in the PsA subgroup (Table S7).

also in 111,027 other papers